- Home
- LXEH vs TENX Comparison
LXEH vs TENX Comparison
Compare LXEH & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- TENX
- Stock Information
- Founded
- LXEH 2001
- TENX 1967
- Country
- LXEH China
- TENX United States
- Employees
- LXEH N/A
- TENX N/A
- Industry
- LXEH Other Consumer Services
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- TENX Health Care
- Exchange
- LXEH Nasdaq
- TENX Nasdaq
- Market Cap
- LXEH 25.1M
- TENX 21.6M
- IPO Year
- LXEH 2020
- TENX N/A
- Fundamental
- Price
- LXEH $2.23
- TENX $5.68
- Analyst Decision
- LXEH
- TENX Strong Buy
- Analyst Count
- LXEH 0
- TENX 3
- Target Price
- LXEH N/A
- TENX $16.00
- AVG Volume (30 Days)
- LXEH 259.9K
- TENX 12.6K
- Earning Date
- LXEH 05-20-2025
- TENX 05-14-2025
- Dividend Yield
- LXEH N/A
- TENX N/A
- EPS Growth
- LXEH N/A
- TENX N/A
- EPS
- LXEH N/A
- TENX N/A
- Revenue
- LXEH $4,493,795.00
- TENX N/A
- Revenue This Year
- LXEH N/A
- TENX N/A
- Revenue Next Year
- LXEH N/A
- TENX N/A
- P/E Ratio
- LXEH N/A
- TENX N/A
- Revenue Growth
- LXEH N/A
- TENX N/A
- 52 Week Low
- LXEH $1.53
- TENX $2.77
- 52 Week High
- LXEH $50.08
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- LXEH 33.81
- TENX 49.30
- Support Level
- LXEH $1.96
- TENX $5.49
- Resistance Level
- LXEH $3.30
- TENX $5.87
- Average True Range (ATR)
- LXEH 0.48
- TENX 0.27
- MACD
- LXEH 0.20
- TENX 0.03
- Stochastic Oscillator
- LXEH 16.28
- TENX 52.04
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.